Results 201 to 210 of about 377,752 (312)

Turner Syndrome and Gender Incongruence: Considerations for Gender Affirming Hormonal Therapy. [PDF]

Case Rep Endocrinol
Urban V, Bangalore-Krishna K.
europepmc   +1 more source

Effects of gender-affirming hormones on lipid, metabolic, and cardiac surrogate blood markers in transgender persons

, 2019
Defreyne, Justine, Rietzschel, Ernst, T'Sjoen, Guy, Van de Bruaene, Laurens, Van Schuylenbergh, Judith   +4 more
core   +1 more source

PTG‐Dependent Glycogen Metabolic Dysfunction Drives Impaired Adipose Browning: A Novel Mechanism Linking PM2.5 to Metabolic Disorders

Advanced Science, EarlyView.
This study provides the first evidence that PM2.5 impairs iWAT browning via PTG‐mediated glycogen metabolism disruption, which is initiated by ADRB3 inhibition and subsequently triggers VEGFB upregulation. It thereby delineates the ADRB3‐PTG‐VEGFB axis as central to PM2.5‐induced metabolic dysfunction and identifies adipose glycogen metabolism as a ...
Limin Wang, Renjie Hu, Yanxi Chai, Ping He, Sanduo Li, Lisha Zhao, Wenbin Zhao, Lu Zhang, Li Qin, Ran Li, Xiaoli Hou, Qinghua Sun, Cuiqing Liu   +12 more
wiley   +1 more source

Efficacy and Safety of Ormeloxifene Versus Conventional Hormonal Therapy in Women With Non-structural Abnormal Uterine Bleeding: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Sulaiman SP, Gunasekaran Kala P, Mohan R, Mary J JF, Tamilarasan P, Xaviar S.   +5 more
europepmc   +1 more source

Proteogenomic Characterization Reveals Subtype‐Specific Therapeutic Potential for HER2‐Low Breast Cancer

Advanced Science, EarlyView.
Multiomic profiling of HER2‐low breast cancer identifies three proteomic subtypes with distinct therapeutic strategies: endocrine, antiangiogenic, and anti‐HER2 therapies. Genomic and lactate modification landscapes are detailed, providing insights for precise management.
Shouping Xu, Keda Yu, Lei Liu, Qin Wang, Xiaohui Wu, Yihai Chen, Guozheng Li, Xin Zhang, Bo Wei, Zitong Fu, Abiyasi Nanding, Zuxianglan Zhao, Lingbing Yang, Xingda Zhang, Jianyu Wang, Wantong Sun, Yi Hao, Zhongyi Cheng, Xiaojiang Cui, Hao Wu, Da Pang   +20 more
wiley   +1 more source

Adherence with hormonal therapy in women with breast cancer: a cross-sectional study in Medellin, Colombia. [PDF]

Colomb Med (Cali)
Puerta Alzate K, Lema Calidonio C, Lema Medina M, Villa García P.   +3 more
europepmc   +1 more source

Dual Targeting of Tau Kinases and Autophagy by Abemaciclib Independent of CDK4/6 Inhibition

Advanced Science, EarlyView.
Abemaciclib rescues cognitive function and attenuates tau pathology in Alzheimer's disease models, but not through its known cancer‐fighting mechanism. This study demonstrates that abemaciclib operates independently of CDK4/6 inhibition, instead directly targeting tau kinases CaMKII and GSK3β while simultaneously promoting autophagic clearance of ...
Jihui Han, June‐Hyun Jeong, Dongjoon Lee, Yujin Jung, Yujin Jin, Eun Sun Jung, Haeng Jun Kim, Woo Youn Kim, Chang‐Han Lee, Inhee Mook‐Jung   +9 more
wiley   +1 more source

Efficacy of Dual Hormonal Therapy with Fulvestrant and Aromatase Inhibitors as Neoadjuvant Endocrine Treatment for Locally Advanced Breast Cancer. [PDF]

Cancers (Basel)
Majić A, Bajić Ž, Ban M, Tica Sedlar I, Čerina Pavlinović D, Petrić Miše B, Strikić A, Tomić S, Vrdoljak E.   +8 more
europepmc   +1 more source

WDR5‐H3K4me3 Epigenetic Axis Promotes TRMT6‐Dependent tRNA M1A Modification to Facilitate Triple‐Negative Breast Cancer Progression by Suppressing Ferroptosis

Advanced Science, EarlyView.
Upregulated TRMT6 forms aberrant hypermethylation of a specific tRNA pool and serves as a predictor of poor prognosis in TNBC. This m1A modification in tRNAs enhances translation of FTH1 and FTL, reducing the pool of bioavailable Fe2⁺. Reduced Fe2+ availability impairs RSL3‐induced lipid peroxidation and tumor progression.
Yuqing Lei, Xue Wang, Jiahe Liu, Zixu Niu, Jiaqi Hua, Qian Guo, Dan Du, Yuanchang Zhu, Fucheng He, Mingxia Zhou, Hongle Li, Jing He, Jun Li   +12 more
wiley   +1 more source

ERM Inhibition Confers Ferroptosis Resistance through ROS‐Induced NRF2 Signaling

Advanced Science, EarlyView.
ERM inhibition disrupts ERM‐actin interactions, elevating ROS and triggering KEAP1 degradation, which stabilizes and activates NRF2. Nuclear NRF2 induces cytoprotective genes, notably HMOX1, enhancing redox buffering and suppressing lipid peroxidation to resist erastin‐induced ferroptosis.
Menghao Qiao, Liqun Zhou, Minhua Zhou, Yu Fang, Haiying Mai, Lingbo Cao, Kun Xu, Yuan Sang, Minyi Chen, Jiewei Huang, Peiyi Huang, Zhipeng Yan, Chao Wang, Zhangshuai Dai, Dichun Huang, Ronghan He, Lijuan Pang, Yunmiao Guo, Ting Gang Chew, Junqi Huang   +19 more
wiley   +1 more source